SYDNEY, April 25, 2026, 08:02 AEST
Cochlear Limited’s shares ended Friday at A$97.35, barely above this week’s low, after a profit warning wiped more than 40% from the Australian hearing-implant maker’s share price across three trading sessions. The stock rose 2.47% on Friday, but remained sharply below Tuesday’s A$167.94 close.
The issue is no longer just one weak update. Investors are testing whether Cochlear’s adult-and-senior implant market is still a defensive growth business — one expected to hold up in a downturn — or a more cyclical procedure market tied to consumer confidence, referrals and hospital capacity. Morningstar analyst Shane Ponraj cut his fair value estimate by 51% to A$110 and said the headwinds looked more structural.
Australia’s share market is closed on Saturday for Anzac Day. ASX Trade said its cash market would be open for trading, clearing and settlement on Monday, leaving the next price test until after the long weekend in New South Wales.
Cochlear cut its FY26 underlying net profit after tax, or NPAT — profit after tax before some items — to A$290 million-A$330 million from a previously published A$435 million-A$460 million range. It also forecast second-half sales growth of 2%-6% in constant currency, a measure that strips out exchange-rate swings.
The company said developed-market implant revenue was flat in the third quarter on a constant-currency basis. It blamed weak U.S. consumer sentiment, fewer referrals from the hearing-aid channel, capacity limits in the UK and Germany, and industrial action in Italy and Spain.
The Middle East added another drag. Cochlear said the conflict could cause order cancellations, delivery delays and up to A$10 million in provisions on receivables, meaning unpaid customer bills; it also pointed to a roughly A$20 million hit from lower factory-cost recovery, A$18 million-A$25 million in cost-base reshaping expenses and a A$25 million after-tax foreign-exchange hit.
Chief Executive Dig Howitt said hearing loss in adults and seniors was still being treated as “a discretionary intervention,” and said the company needed to keep pushing to “medicalise hearing loss.” He also said Cochlear remained confident in its market position and cited strong adoption of the Nucleus Nexa System.
Reuters reported that Cochlear shares fell 40.7% on Wednesday to A$99.58, their weakest close since March 2016. The midpoint of the new profit range also missed the Visible Alpha consensus estimate of A$402.5 million by a wide margin.
The selling did not stop there. ABC News reported Cochlear closed Thursday down 4.6% at A$95.00, after touching A$91.33 earlier in the session, before Friday’s modest rebound.
Broker cuts followed. Market Index reported that Citi downgraded Cochlear to Sell and cut its target to A$95 from A$210, UBS moved to Neutral from Buy and cut its target to A$109 from A$302, while Morgan Stanley lifted the rating to Equal-weight from Underweight but cut its target to A$119 from A$194.
Morgans healthcare analyst Derek Jellinek wrote that “near-term earnings visibility has deteriorated materially” and that demand appeared “more cyclical than previously assumed,” Stockhead reported. Morgans kept a Hold rating but cut its 12-month target price to A$107.17 from A$214.93. Stockhead
The warning also hit hearing-health peers in Europe. MarketScreener reported that Demant, Sonova and Amplifon fell after Cochlear’s update, with investors reading the U.S. consumer-sentiment weakness across companies exposed to North America.
But the risk runs both ways. A quicker recovery in U.S. referrals, European surgery capacity or Middle East deliveries could help the company defend the new outlook; a lasting shift by adults and seniors to delay implant procedures would likely mean more spending on referrals and market development, while weaker volumes keep pressure on margins.
Not every line in the update was weak. Cochlear said services revenue rose 13% in the third quarter in constant currency and acoustics revenue rose 11%, but the central question for investors is still the bigger one: when the implant business starts growing again, and at what cost.
